Search results
Results from the WOW.Com Content Network
Shop right, in United States patent law, is an implied license under which a firm may use a patented invention, invented by an employee who was working within the scope of their employment, using the firms' equipment, or inventing at the firms' expense.
A royalty payment is a payment made by one party to another that owns a particular asset, for the right to ongoing use of that asset. Royalties are typically agreed upon as a percentage of gross or net revenues derived from the use of an asset or a fixed price per unit sold of an item of such, but there are also other modes and metrics of compensation.
Assign rights to a subject invention only to an organization having as a primary function the management of inventions, unless approved by the Federal agency; Share royalties with the inventor; Use the balance of royalties after expenses for scientific research or education; Make efforts to attract, and give preference to, small business licensees.
Patent monetization refers to the generation of revenue or the attempt to generate revenue by a person or company by selling or licensing the patents it owns. Some of these owners try to make money from patents on inventions they develop, manufacture or market.
ASI Entertainment Receives First Royalties SEATLLE--(BUSINESS WIRE)-- ASI Entertainment, Inc. (OTCQB:ASIQ) announced today that it has received royalties from its intellectual property licensed to ...
Offensive patent aggregation – purchasing of patents in order to assert them against companies that would use the inventions protected by such patents (operating companies) and to grant licenses to these operating companies in return for licensing fees or royalties. Open patent – patented invention that can freely be distributed under a ...
The term "cross licensing" implies that neither party pays monetary royalties to the other party, although this may be the case. For example, Microsoft and JVC entered into a cross license agreement in January 2008. [3] Each party, therefore, is able to practice the inventions covered by the patents included in the agreement. [4]
the patented invention is not available to the public at a reasonably affordable price, or, the patented invention is not worked [25] in the territory of India. In March 2012, India granted its first compulsory license ever to Indian generic drug manufacturer Natco Pharma for Sorafenib tosylate, a cancer drug patented by Bayer. [26]